TSOI stock (OTCPINK) is moving higher on December 17, 2019, after the company announced a letter of intent to license exclusive rights to a patented adult stem cell for treatment of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) within the field of sports and athletics.
This company has a lot of buzz surrounding it over the past couple of weeks and really seems to be making big moves.
On December 16, 2019, Therapeutic Solutions International (OTCPINK: TSOI), announced the signing of a Letter of Intent to license exclusive rights to a patented adult stem cell for treatment of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) within the field of sports and athletics.
The stem cell is unique in that it possesses features of mesenchymal stem cells, however, it outperforms mesenchymal cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.
Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.
“Back in the summer of 2018 Wes Chandler introduced myself and our team to the terrible condition known as CTE and we have worked with Wes and his team ever since on numerous levels to develop a strategy for combatting CTE and Traumatic Brain Injury (TBI),” said Timothy Dixon, President, and CEO of TSOI. “Many of our recent developments within the field of CTE and TBI was a direct result of the leadership provided by Wes so we could fully appreciate the devastation this injury causes and develop our products to that end. We are honored deeply today to engage with Wes Chandler on this timely and mission-critical program.”
“The advantage of the stem cell we are licensing is that it has already been utilized in clinical trials intravenously and possesses an excellent safety record,” said Wes Chandler, CEO of WCTE, Inc. “Through working with our team of internationally renowned scientists, we are confident in filing an Investigational New Drug (IND) application with the FDA for Chronic Traumatic Encephalopathy within the First Quarter of 2020 This will position us to provide not just prophylactic approaches to this terrible condition, but begin the process of developing a treatment that has a shot of actually reversing brain damage.”
In a recent article published by Alexi Cohen in the Boston Harold titled “CTE risk, severity increases with years playing football, study shows” Ms. Cohen stated in part that, “The risk and severity of developing the life-altering disease, chronic traumatic encephalopathy, increases with the number of years playing football according to a new study that researchers say affirms a strong relationship between football and CTE.
“We have sufficient data now to say that we are very confident that this relationship that we are finding is not due to chance, it’s a clear relationship,” said Dr. Jesse Mez, lead author on the study and director of the Boston University Alzheimer’s Disease Center. The risk of developing CTE increased by 30% for each year of playing football, the data out of the Boston University CTE Center showed.
Among those who already had CTE, the odds of developing a severe form of the disease increased by 14% for each additional year of football played. The study examined the brains of 223 deceased amateur and professional football players with CTE and 43 without the disease. All of the samples underwent a complete neuropathological evaluation. Mez said he hopes the findings lead others to make “thoughtful decisions about play” and understand the risks involved in tackle football.
“I would not let my kids play football given these results,” said Mez. Men who played football for more than 14.5 years were 10 times more likely to develop CTE than those who played fewer, according to the report published in Annals of Neurology on October 7, 2019.
On December 12, 2019, Therapeutics Solutions International announced the signing of a Master Sales Agreement with Tiva Bio to distribute the nutraceutical line of products developed by TSOI.
Products to be included in the Master Sales Agreement currently consists of NanoStilbene, NeuroStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and ProJuvenol. Future products will be added to the Master List as commercialized.
“After more than a year of discussions, collaborations, and demonstrating the potent properties of our products with Wes Chandler and his Team, we are very excited to execute this sales agreement with our great friends at Tiva Bio, a Wes Chandler Company, focused on biotechnology, their mission is to discover, develop, and bring to market novel products that are designed to provide relief to an array of symptoms including CTE, pain, nausea, anxiety, and inflammation,” said Timothy Dixon, President, and CEO of TSOI. “The Team Wes has assembled in areas of science, marketing, and branding is second to none. We are fortunate to work with such a well-fitted and synergistic partner. This agreement only marks the beginning of a long and beneficial relationship focused on providing preventative and treatment approaches to chronic traumatic encephalopathy.”
On November 11, 2019, Therapeutics Solutions International announced the signing of a Letter of Intent with Beijing Regenesis Biotechnology Co. Ltd., of Beijing China to develop and commercialize the anti-aging properties of cord blood plasma combined with NanoStilbene.
“Our Company is the leading entity in implementation of anti-aging regenerative medicine in China. We have previously commercialized novel technologies for rejuvenation of testicular and ovarian function,” said Dr. Fei Li, Chief Executive Officer of Beijing Regenesis. “Cord blood components have been used for more than a Century in medicine with an excellent safety profile. We are excited to utilize the new technology developed by TSOI in order to reduce and potentially even reverse the biological aspects of aging.”
“Having previously collaborated with Beijing Regenesis, I am excited to expand our work in the area of anti-aging medicine. There are publications from Stanford University and Harvard University that have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effect on organs/tissues of aged mice. Following this logic, other studies have demonstrated that human cord blood plasma, when administered to aged mice results in restoration of brain function and improved cellular function in the hippocampus,” said Dr. Feng Lin, Chief Scientific Officer of TSOI. “We are very excited to commercialize the use of cord blood plasma with NanoStilbene as a means of translating the animal parabiosis experiments into humans.”
“Our Company is about fast forwarding the development of novel medical technologies. Based on the reputation, success, and ingenuity of Beijing Regenesis, we believe we have found an ideal commercialization partner,” said Timothy Dixon, President and Chairman of TSOI. “We are especially grateful for Congressional Candidate Famela Ramos, our Director of Business Development, for having arranged our meeting and providing an excellent venue for signing of the Letter of Intent.”